Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...
Novartis gets FDA accelerated approval for kidney disease treatment
Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...
GlobalData on MSN14h
FDA grants accelerated approval to Novartis’ Vanrafia for IgAN
The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
Managed Healthcare Executive5h
FDA Grants Accelerated Approval to Vanrafia for IgAN, a Rare Kidney Disease
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
MPR5h
Vanrafia Gets Accelerated Approval for Immunoglobulin A Nephropathy
The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
The Pharma Letter12h
FDA accelerated approval for Novartis’ Vanrafia
Swiss pharma giant Novartis (NOVN: VX) today announced the US Food and Drug Administration (FDA) has granted accelerated ...
Sportskeeda5h
KKR vs SRH: Who won yesterday’s IPL 2025 match?
Kolkata Knight Riders (KKR) beat Sunrisers Hyderabad (SRH) by 80 runs in yesterday's IPL 2025 match at the Eden Gardens.
Physician's Weekly9h
Q&A: Targeting APRIL in IgA Nephropathy Shows Promise
Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...
Medical Dialogues13h
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...
Fierce Pharma9h
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
Novartis gets FDA accelerated approval for Vanrafia
Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...